Steroid use and misuse: a key performance indicator in the management of IBD

被引：11

作者：

Blackwell, Jonathan ^{[1
,2
]}

Selinger, Christian ^{[3
,4
]}

Raine, Tim ^{[5
]}

Parkes, Gareth ^{[6
]}

Smith, Melissa A. ^{[7
,8
]}

Pollok, Richard ^{[1
,9
]}

机构：

[1] St Georges Hosp NHS Fdn Trust, Dept Gastroenterol, London, England

[2] Imperial Coll London, Sch Publ Hlth, London, England

[3] Leeds Teaching Hosp NHS Trust, Leeds Gastroenterol Inst, Leeds, W Yorkshire, England

[4] Univ Leeds, Leeds Inst Res St James, Leeds, W Yorkshire, England

[5] Cambridge Univ Hosp NHS Fdn Trust, Dept Gastroenterol, Cambridge, England

[6] Royal London Hosp, Dept Gastroenterol, London, England

[7] Brighton & Sussex Univ Hosp NHS Trust, Digest Dis Ctr, Brighton, E Sussex, England

[8] Brighton & Sussex Med Sch, Dept Gastroenterol, Brighton, E Sussex, England

[9] St Georges Univ London, Div Infect & Immun, London SW17 0RE, England

来源：

FRONTLINE GASTROENTEROLOGY | 2021年 / 12卷 / 03期

基金：

英国惠康基金;

关键词：

steroid-sparing efficacy; inflammatory bowel disease; ulcerative colitis; crohn's disease; 5-aminosalicylic acid (5-ASA); INFLAMMATORY-BOWEL-DISEASE; ACTIVE ULCERATIVE-COLITIS; MAINTENANCE THERAPY; CORTICOSTEROID-THERAPY; 5-AMINOSALICYLIC ACID; ADRENAL INSUFFICIENCY; ORAL CORTICOSTEROIDS; SELF-MEDICATION; BUDESONIDE FOAM; CROHNS;

D O I：

10.1136/flgastro-2019-101288

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Corticosteroids remain an important tool for inducing remission in inflammatory bowel disease (IBD) but they have no role in maintenance of remission. The significant adverse side effect profile of these drugs means their use should be avoided where possible or measures taken to reduce their risk. Despite an expanding array of alternative therapies, corticosteroid dependency and excess remain common. Appropriate steroid use is now regarded a key performance indicator in the management of IBD. This article aims to outline indications for corticosteroid use in IBD, their risks and strategies to reduce their use and misuse.

引用

页码：207 / 213

页数：7

共 50 条

[1] LINE USE AT FIRST DIALYSIS, IS THIS A VALID KEY PERFORMANCE INDICATOR?
Li, C.
Kairaitis, L.
[J]. NEPHROLOGY, 2013, 18 : 67 - 67
[2] Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients
Selinger, Christian P.
Parkes, Gareth C.
Bassi, Ash
Limdi, Jimmy K.
Ludlow, Helen
Patel, Pritash
Smith, Melissa
Saluke, Santosh
Ndlovu, Zandile
George, Becky
Saunders, John
Adamson, Mark
Fraser, Aileen
Robinson, Jenna
Donovan, Fiona
Parisi, Ioanna
Tidbury, Jude
Gray, Lynn
Pollok, Richard
Scott, Glyn
Raine, Tim
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (09) : 1009 - 1018
[3] DEVELOPMENT OF KEY PERFORMANCE INDICATOR FOR MANAGEMENT OF UNDER DEPOSIT CORROSION (UDC)
Garcia, Alfonso
Place, Trevor
Wood, Stephen
[J]. PROCEEDINGS OF THE 11TH INTERNATIONAL PIPELINE CONFERENCE, 2016, VOL 1, 2017,
[4] Use of key performance indicators in production management
Jovan, Vladimir
Zorzut, Sebastjan
[J]. 2006 IEEE CONFERENCE ON CYBERNETICS AND INTELLIGENT SYSTEMS, VOLS 1 AND 2, 2006, : 689 - +
[5] The use of Key Performance Indicator in Malaysian Government-Linked Company
Abu Bakar, Noor Raudhiah
Abu Kasim, Nor Aziah
Mustapha, Mazlina
Amiruddin, Rozita
[J]. PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON ECONOMICS AND BANKING 2015, 2015, 5 : 250 - 259
[6] Use of the Safe System Assessment Framework as a Safety Key Performance Indicator
McHeim, Brayden
Matters, Ben
Steinmetz, Lisa
Turner, Blair
[J]. JOURNAL OF ROAD SAFETY-JRS, 2021, 32 (01): : 37 - 44
[7] Letter to Editor Regarding Narula et al, IBD 2017, Budenoside Use Is a Key Quality Marker in the Management of IBD
Pollok, Richard C. G.
Saxena, Sonia
Alexakis, Chris
Chhaya, Vivek
[J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 (08) : E41 - E41
[8] THE USE AND MISUSE OF PERFORMANCE TESTING
DREISINGER, TE
[J]. ORTHOPEDICS, 1994, 17 (05) : 473 - 477
[9] Customer value as a key performance indicator (KPI) and a key improvement indicator (KII)
Setijono, Djoko
Dahlgaard, Jens J.
[J]. MEASURING BUSINESS EXCELLENCE, 2007, 11 (02) : 44 - 61
[10] Drug use and treatment misuse: Key points on polydrug use
Deschenau, Alice
Iftimovici, Anton
Touzeau, Didier
[J]. PRESSE MEDICALE, 2016, 45 (12): : 1102 - 1107

← 1 2 3 4 5 →